Q4 2024 Harrow Inc Earnings Call Transcript
Key Points
- Harrow Inc (HROW) reported a record financial performance for 2024, with a 53% increase in full-year revenues to $199.6 million.
- The company achieved a remarkable 84% increase in fourth-quarter revenue compared to the same period in 2023.
- Adjusted EBITDA increased by 43% to $40.3 million for the full year 2024.
- The company's core gross margins improved significantly, reaching 84% for Q4 and 80% for the full year.
- Harrow Inc (HROW) launched the VEVYE Access for All program, which aims to improve patient access and affordability, potentially boosting prescription volumes and revenue growth.
- The company experienced a delay in filing its Form 10-K due to a merger with a new auditing firm.
- There may be quarter-to-quarter volatility in unit demand for IHEEZO, despite its strong performance.
- Harrow Inc (HROW) anticipates starting to pay taxes in 2025, which could impact cash flow.
- The company extended payment terms for distributors, impacting cash flow in Q4.
- Harrow Inc (HROW) plans to stop reporting prescription data to IQVIA, which may reduce the accuracy and actionability of data for stockholders.
Good morning, and welcome to Harrow's fourth quarter and year end 2024 earnings conference call. My name is Gigi, and I'll be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference is being recorded.
I would now like to turn the call over to Jamie Webb, Director of Communications and IR for Harrow.
Thank you, operator. Good morning, and welcome to Harrow's fourth quarter and year end 2024 earnings conference call. Before we begin today, let me remind you that the company's remarks may include forward-looking statements within the meaning of federal securities laws. F
orward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risk and uncertainties related to the company's ability to make commercially available its
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
